Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Radioactive therapy takes aim at childhood cancer

NCT ID NCT00107289

First seen Dec 08, 2025 · Last updated Jun 08, 2026 · Updated 24 times

Summary

This study tests a radioactive drug called I-MIBG in people with neuroblastoma (a nerve cancer) or pheochromocytoma/paraganglioma (adrenal tumors) that have not responded to standard treatments. The drug seeks out and delivers radiation directly to cancer cells. The goal is to see how well it shrinks tumors and what side effects occur. About 200 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHEOCHROMOCYTOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

  • Contact

    Phone: •••-•••-••••

Locations

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-••••

    Contact

    Contact Phone: •••-•••-••••

Conditions

The condition(s) this trial relates to.

neuroblastoma pheochromocytoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.